Company intelligence / Profile preview
AM-Pharma
Utrecht, Utrecht, Netherlandsam-pharma.com ↗
- Ownership
- Private
- Employees
- ~23
- Development stage
- Phase 3
01
Overview
AM‑Pharma is a clinical-stage biopharmaceutical company developing ilofotase alfa, a proprietary recombinant human alkaline phosphatase. The lead program targets prevention and treatment of cardiac surgery-associated renal damage and rare disease hypophosphatasia. The company has initiated a Phase 2 trial for ilofotase alfa in CSA-RD. Pfizer previously acquired an option to purchase the remaining equity upon completion of certain milestones.
- Therapeutic areas
- Rare DiseasesCardiovascularNephrology
- Modalities
- Protein therapeuticsEnzyme therapy (recombinant human alkaline phosphatase)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Pfizer held an option to acquire the company after certain milestones were met
Beyond the preview
Go deeper on AM-Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AM-Pharma.